source
- FDA advisory panel backs Replimune's melanoma therapy RP1, raising approval prospectsAdvisors to the U.S. Food and Drug Administration voted 10-3 in favor of Replimune's experimental melanoma treatment, RP1, despite lingering scientific concerns about the data presented. The panel…
- FTC Sues Hims & Hers for Alleged Illegal Sharing of Patient Data and Deceptive BillingThe Federal Trade Commission has filed a lawsuit against Hims & Hers, a California‑based telehealth company, accusing it of violating privacy laws. The complaint says the firm used tracking pixels…